<DOC>
	<DOCNO>NCT00369460</DOCNO>
	<brief_summary>RATIONALE : Measuring change muscle tissue patient cancer may help doctor predict well patient respond treatment , may help study cancer future . PURPOSE : This pilot study evaluate change muscle tissue patient pancreatic cancer .</brief_summary>
	<brief_title>Changes Muscle Tissue Patients With Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Demonstrate decrease/increase fat-free mass ( FFM ) 10 % baseline , base tumor progression/regression , within patient inoperable locally advanced metastatic pancreatic carcinoma . - Determine correlation change FFM 6-month survival . - Confirm frequency lymphocytopenia patient inoperable locally advanced metastatic pancreatic carcinoma . - Demonstrate interaction pretreatment total lymphocyte count , treatment response , 6-month survival patient inoperable locally advanced metastatic pancreatic carcinoma . - Collect adjuvant information , weight , body mass index , age , ECOG performance status , gait speed , concomitant medication , CA19-9 , total lymphocyte count , patient . OUTLINE : This pilot study . Patients weight , body mass index , age , ECOG performance status , gait speed , concomitant medication , CA19-9 , total lymphocyte count measure start cancer treatment patient 's choosing . Patients re-assessed approximately 2 month , 4 month , 6 month , change tumor burden . PROJECTED ACCRUAL : A total 17 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven inoperable locally advanced metastatic pancreatic adenocarcinoma PATIENT CHARACTERISTICS : ECOG performance status 03 Must able stand unassisted scale Must pacemaker implant defibrillator PRIOR CONCURRENT THERAPY : Prior chemotherapy radiotherapy allow No concurrent use follow : Corticosteroids Steroids antiemetic associate chemotherapy allow Anabolic steroid Thalidomide Megesterol Eicosapentaenoic acid ( EPA ) Nutritional supplement without EPA allow Juven Concurrent enrollment clinical trial allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>